-- コマース・バンクシェアーズ(CBSH)は火曜日、取締役会が自社株買いプログラムの対象となる株式数を250万株増やすことを承認したと発表した。 同社は、既に承認済みの株式を含め、最大750万株まで自社株買いできる権限を得たと述べた。 株価は午前の取引で約2%上昇した。
Price: $52.02, Change: $+1.00, Percent Change: +1.96%
-- コマース・バンクシェアーズ(CBSH)は火曜日、取締役会が自社株買いプログラムの対象となる株式数を250万株増やすことを承認したと発表した。 同社は、既に承認済みの株式を含め、最大750万株まで自社株買いできる権限を得たと述べた。 株価は午前の取引で約2%上昇した。
Price: $52.02, Change: $+1.00, Percent Change: +1.96%
3:00 Tuesday vs 3:00 Monday2yr 99-26 vs 100-04; 3.842% vs 3.799%5yr 99-16+ vs 99-21+; 3.981% vs 3.947%10yr 98-06+ vs 98-10+; 4.351% vs 4.335%30yr 97-00 vs 96-31+; 4.941% vs 4.941%2/10 50.633 bps vs 53.307 bps5/30 95.813 bps vs 99.249 bps
Brown & Brown's (BRO) Q1 report shows that the company's organic revenue growth continues to remain under pressure despite better than expected quarterly earnings per share and adjusted margins, UBS said in a note.The company's flat Q1 organic revenue growth was below UBS expectations of a 2% growth and consensus of 1.3%, UBS said on Monday. The metric further excluded $10 million in litigation related lost revenue, which was in-line with expectations, according to UBS.Looking ahead, Brown & Brown expects catastrophe property rates to continue to experience downward pressure in Q2, while economic growth should remain relatively stable, UBS said. The company's capital allocation will have a bias toward buybacks and paying down debt, while remaining active for specialty and smaller deals, UBS added.UBS maintained its neutral rating on the company's stock with an $81 price target.Shares of Brown & Brown were down over 6% in Tuesday trading.Price: $62.07, Change: $-4.06, Percent Change: -6.13%
Incyte (INCY) has an average rating of overweight and mean price target of $109.10, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $94.83, Change: $-0.89, Percent Change: -0.93%